A Phase I Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an RSV-F Protein Nanoparticle Vaccine, With or Without Aluminum Adjuvant, and Co-administered With a Licensed Inactivated Influenza Vaccine, in Healthy Subjects ≥ 60 Years of Age.

Trial Profile

A Phase I Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an RSV-F Protein Nanoparticle Vaccine, With or Without Aluminum Adjuvant, and Co-administered With a Licensed Inactivated Influenza Vaccine, in Healthy Subjects ≥ 60 Years of Age.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2014

At a glance

  • Drugs RSV F protein vaccine-Novavax (Primary) ; Aluminium phosphate; Influenza virus vaccine
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Sponsors Novavax
  • Most Recent Events

    • 12 May 2014 Top-line 1-year follow-up results reported in a Novavax media release.
    • 04 Mar 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
    • 05 Feb 2014 Planned End Date changed from 1 Oct 2013 to 1 Feb 2014 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top